Managing dyslipidaemia and diabetes
Dyslipidaemia, characterised by abnormal cholesterol and triglyceride levels, often coexists with diabetes and plays a crucial role in exacerbating cardiovascular disease (CVD) risk in individuals living with diabetes.
Managing both dyslipidaemia and diabetes in a holistic manner is critical to reducing CVD risk and enhancing patient outcomes and involves a multifaceted approach encompassing both lifestyle and pharmacological interventions.
This session will explore the key recommendations of the ESC 2019 dyslipidaemias guidelines and NICE (NG238) CVD guidelines to help assess and reduce risks in your patients living with diabetes.
The session will also cover guidance for lipid modification with pharmacological agents. As the pharmacological arsenal available to primary care has moved far beyond statins and we explore the agents now at our disposal. We will help to demystify these agents and simplify their use in practical terms to help you achieve the cholesterol targets to best manage CVD risk.